| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-02-27 | Rekynda™ (bremelanotide) | pre-menopausal women diagnosed with hypoactive sexual desire disorder (HSDD) | 3 | Amag Pharmaceuticals (USA - MA) Palatin Technologies (USA - NJ) | Women health |
| 2017-02-27 | Trulance™ (plecanatide) | chronic idiopathic constipation (CIC) | 3 | Synergy Pharmaceuticals (USA - NY) | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases |
| 2017-02-24 | Taksta™ (CEM-102, sodium fusidate, sodium salt of fusidic acid) | acute bacterial skin and skin structure infections (ABSSSI) | 3 | Cempra (USA - NC) | Infectious diseases |
| 2017-02-24 | TroVax® (MVA-5T4 Immunotherapy) | colorectal cancer | 2 | Oxford Biomedica (UK) | Cancer - Oncology (UK) |
| 2017-02-24 | V212 | herpes zoster | 3 | Merck&Co (USA - NJ) | Infectious diseases |
| 2017-02-24 | IMO-2125 in combination with ipilimumab or pembrolizumab | patients with metastatic melanoma with disease that is refractory to PD-1 inhibitors. | 1-2 | Idera Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-02-23 | DX-2930 - lanadelumab | prevention of hereditary angioedema (HAE) attacks | 1b | Dyax (USA - MA), now Shire (UK - USA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-02-23 | Baremsis™ - APD421 (amisulpride - intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) | post-operative nausea & vomiting (PONV) | Acacia Pharma (UK) | Gastrointestinal diseases - Digestive diseases | |
| 2017-02-23 | Toca 511 & Toca FC | glioblastoma multiforme, anaplastic astrocytoma | 2-3 | Tocagen (USA - CA) | Cancer - Oncology |
| 2017-02-23 | GLPG2451 and GLPG2222 | cystic fibrosis | 1 | Galapagos (Belgium) | Rare diseases - Genetic diseases |
| 2017-02-23 | tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate) | renal cell carcinoma (RCC) | 3 | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2017-02-23 | antiviral molecules with potential for Dengue virus treatment | dengue fever | preclinical | Abivax (France) | Infectious diseases |
| 2017-02-23 | Bronchitol® (mannitol) | cystic fibrosis | 3 | Pharmaxis (Australia) | Rare diseases - Genetic diseases |
| 2017-02-21 | MOR107 (formerly LP2) | 1 | Lanthio Pharma, Morphosys ' subsidiary (The Netherlands) | ||
| 2017-02-21 | ATX-MS-1467 | relapsing multiple sclerosis (RMS) | 2a | Apitope (UK) | Autoimmune diseases |
| 2017-02-20 | savolitinib | pulmonary sarcomatoid carcinoma | 2 | Hutchison China MediTech Limited "ChiMed" (China) | Cancer - Oncology |
| 2017-02-19 | Tecentriq® (atezolizumab) and Avastin® (bevacizumab) | renal cell carcinoma | 2 | Roche (Switzerland) | Cancer - Oncology |
| 2017-02-17 | Entyvio® (vedolizumab) | moderately to severely active ulcerative colitis, Crohn's disease | 3 | Takeda Pharmaceutical (Japan) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2017-02-17 | tivantinib (ARQ 197) | hepatocellular carcinoma | 3 | ArQule (USA - MA) Daiichi Sankyo (Japon) | Cancer - Oncology |
| 2017-02-17 | CT-P13 - Inflectra®/Remsima® (biosimilar infliximab) | Crohn's disease | 3 | Celltrion Healthcare (South Korea) Pfizer (USA - NY) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
